Molecular mechanism of Tongmai Yangxin Pill intervention in elderly patients with coronary heart disease

Z.-W. Xiao, Y. Liu, Z.-Y. Li, S. Li, L.-H. Qin

Department of Food and Drug Engineering, School of Pharmacy, Key Laboratory of Hunan Province for Prevention and Treatment of Integrated Traditional Chinese and Western Medicine on Cardiocerebral Diseases, School of Nursing, School of Informatics, Hunan University of Chinese Medicine, Hunan, Changsh, P.R. China. 479157643@qq.com

---

• Bioinformatics
• Cardiosurgery
• Geriatrics

OBJECTIVE: The Tongmai Yangxin Pill (TMYX) is considered an effective treatment for coronary heart disease (CHD). However, its mechanism is unclear. This study aimed at exploring the molecular mechanisms and key genes of the TMYX in the treatment of CHD.

MATERIALS AND METHODS: Differentially expressed genes (DEGs) in the GSE142008 dataset were screened with the R software, and Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses were performed. Then, protein-protein interactions were analyzed using the Search Tool for the Retrieval of Interacting Genes database. The correlation analysis between key genes was conducted, and gene expression was verified.

RESULTS: A total of 1,614 DEGs were identified, including 1,591 upregulated and 23 downregulated genes. GO enrichment analysis revealed that 240 biological processes, 44 cellular components, and 23 molecular functions were significantly enriched for DEGs in elderly patients with CHD. Similarly, 36 KEGG terms were significantly enriched for DEGs. Ten key genes were screened, and after verification and analysis, seven key genes (RSL24D1, NMD3, DCAF13, WDR36, SDAD1, KRR1, and RPF1) were identified as significantly overexpressed.

CONCLUSIONS: We identified seven key genes as candidate biomarkers for TMYX in the treatment of elderly patients with CHD; these results can serve as a theoretical basis for targeted therapy.

Free PDF Download